U.S. markets open in 4 hours 54 minutes
  • S&P Futures

    3,917.00
    -5.50 (-0.14%)
     
  • Dow Futures

    31,942.00
    +26.00 (+0.08%)
     
  • Nasdaq Futures

    13,214.75
    -87.25 (-0.66%)
     
  • Russell 2000 Futures

    2,296.20
    +11.10 (+0.49%)
     
  • Crude Oil

    63.48
    +0.26 (+0.41%)
     
  • Gold

    1,786.60
    -11.30 (-0.63%)
     
  • Silver

    27.99
    +0.06 (+0.20%)
     
  • EUR/USD

    1.2217
    +0.0049 (+0.40%)
     
  • 10-Yr Bond

    1.3890
    0.0000 (0.00%)
     
  • Vix

    21.89
    -1.22 (-5.28%)
     
  • GBP/USD

    1.4161
    +0.0020 (+0.14%)
     
  • USD/JPY

    106.1050
    +0.2230 (+0.21%)
     
  • BTC-USD

    49,115.85
    -1,719.60 (-3.38%)
     
  • CMC Crypto 200

    981.39
    -13.27 (-1.33%)
     
  • FTSE 100

    6,690.28
    +31.31 (+0.47%)
     
  • Nikkei 225

    30,168.27
    +496.57 (+1.67%)
     

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
Solid Biosciences Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 8:20 am ET. Following the prepared remarks, several members of the leadership team will be available for Q&A.

Institutional investors interested in meeting with management during the conference may reach out to their J.P. Morgan representative.

A live webcast of the presentation will be available on the Events page of the Investors section of the Company website or by clicking here. A webcast replay will be archived for approximately 30 days on the Events page.

About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001. For more information, please visit www.solidbio.com.

Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com

Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com